#United States #California #CAR T Therapy #Gilead #Kite

Gilead and Kite Set to Unveil Innovative Cancer Therapy Data at 2025 ASCO and EHA Meetings

Gilead Sciences, headquartered in Foster City, California, and its subsidiary Kite, based in Santa Monica, California, are unveiling an array of more than 20 abstracts at upcoming major scientific gatherings: the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting from May 30 to June 3, and the 2025 European Hematology Association (EHA) Annual Meeting from June 12 to 15. These findings will spotlight substantial advances concerning triple-negative breast cancer (TNBC), multiple myeloma, and early data on CAR T-cell therapies aimed at brain tumors, emphasizing the companies' commitment to addressing challenging cancers.

Key Highlights of the Presentation

At ASCO, Gilead will present the latest data from the Phase III ASCENT-04/KEYNOTE-D19 trial. This study evaluates the efficacy of Trodelvy (sacituzumab govitecan) in combination with Keytruda (pembrolizumab) as a primary therapy for patients with PD-L1-positive, unresectable locally advanced, or metastatic triple-negative breast cancer (mTNBC). The findings will demonstrate a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when compared to chemotherapy combined with pembrolizumab, a notable milestone in oncology treatment strategies (Abstract #LBA109).

Additionally, researchers at Kite, in collaboration with the University of Pennsylvania Perelman School of Medicine, will present results from a Phase I trial exploring a dual-targeted approach utilizing novel CAR T-cell therapy in patients with recurrent glioblastoma (Abstract #102).

Meanwhile, during the EHA meeting, Kite and its partner Arcellx will disclose the latest outcomes from the Phase II iMMagine-1 trial focusing on anitocabtagene-autoleucel (anito-cel) for relapsed/refractory multiple myeloma (Abstract #S201). This joint development represents a significant advancement in the continuous effort to revolutionize cancer treatments.

A Response to Urgent Medical Needs

Dietmar Berger, MD, PhD, Chief Medical Officer of Gilead Sciences, commented, "Our oncology portfolio is designed to innovate next-generation therapies and combinational treatments to improve patient outcomes. The data we will showcase at ASCO and EHA encompass new pipelines utilizing antibody-drug conjugates and cellular therapies that will drive innovation in oncology and revolutionize clinical practice."

Overview of Selected Abstracts at ASCO and EHA

The ASCO Annual Meeting will include abstracts covering a variety of tumor types, highlighting groundbreaking findings:
1. mTNBC: Abstract #LBA109 discussing Trodelvy combined with Pembro vs. chemo + Pembro.
2. Lung Cancer: Abstract #8599 focusing on long-term follow-up comparing sg with docetaxel in metastatic NSCLC patients.
3. Endometrial Cancer: Abstract #e17624 delving into Trop-2 expression and its prognostic implications based on real-world data.
4. Glioblastoma: Abstract #102 on the efficacy of dual-targeted CAR T in recurrent cases.

Similarly, specific abstracts selected for EHA will include topics such as:
1. Acute Lymphoblastic Leukemia: Abstract #PF374 on Brexucabtagene Autoleucel's five-year survival outcomes.
2. Large Cell Lymphoma: Abstract #PF1168 discussing cost-effectiveness in real-world secondary treatments.
3. Multiple Myeloma: Abstract #S201 revealing findings from the iMMagine-1 trial on anito-cel.

Commitment to Patient Care

Gilead and Kite’s commitment to developing new therapies is evident in their continued investment in research and collaborations. Trodelvy, a first-in-class TROP-2 targeting antibody-drug conjugate, is currently approved in over 50 countries for treating mTNBC after two or more systemic therapies and is under investigation for its effectiveness across various oncology settings.

Additionally, anitocabtagene autoleucel, in partnership with Arcellx, is progressing through clinical trials for multiple myeloma and reflects significant advancements as the partnership aims to commercialize the therapy effectively.

As Gilead and Kite aim to address some of the most challenging cancers of our time, the upcoming presentations at the 2025 ASCO and EHA meetings promise to unveil vital data that could redefine treatment protocols and ultimately improve patient outcomes in oncology. Their endeavor signifies a broader commitment to tackle difficult diseases amid a constantly evolving landscape of oncology and patient care.